Biomea Fusion, Inc.
BMEA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.60
KIRA · Stoqly’s AI analyst, in plain words
- Biomea Fusion, Inc. had $1.9M of revenue in fiscal 2025, down 67.1% on the year before.
- Its operating margin was −4,494.7%, down 1,942.1 pts: of every 100 in sales, about −4,495 is left after running the business.
- Biomea Fusion, Inc. lost $61.8M in fiscal 2025.
Market cap
$43.4M
P/E
—
Revenue
$1.9M
Net income
−$61.8M
Free cash flow
—
Operating margin
−4,494.7%
Biomea Fusion, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−67.1%
No. Sales fell 67.1% last year.
Does it make a profit?
−3,326.0%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biomea Fusion, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- Biomea Fusion, Inc.
- CIK
- 0001840439
Biomea Fusion, Inc. · BMEA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $8.9M | $5.6M | $1.9M |
| Revenue growth | — | — | — | −36.4% | −67.1% |
| Net interest income | — | — | $8.9M | $5.6M | $1.9M |
| Operating margin | — | — | −1,420.4% | −2,552.6% | −4,494.7% |
| Net income | −$41.6M | −$81.8M | −$117M | −$138M | −$61.8M |
| Net margin | — | — | −1,320.4% | −2,452.6% | −3,326.0% |
| Diluted EPS | −$1.74 | −$2.80 | −$3.44 | −$3.83 | −$1.18 |
| Cash | |||||
| Cash from operations | −$35.4M | −$62.4M | −$96.6M | −$120M | −$70.4M |
| Capital expenditure | $3.2M | $1.0M | $3.4M | $0.4M | — |
| Free cash flow | −$38.6M | −$63.4M | −$100.0M | −$120M | — |
| FCF margin | — | — | −1,125.7% | −2,130.7% | — |
| Share count change | 126.5% | 22.7% | 16.5% | 5.9% | 44.7% |
| Debt and strength | |||||
| Cash and short-term investments | $174M | $113M | $177M | $58.3M | $55.8M |
| Shareholders' equity | $179M | $109M | $169M | $51.6M | $29.6M |
| Current ratio | 38.1x | 6.2x | 7.8x | 3.2x | 5.2x |
| Returns and quality | |||||
| Return on equity | −45.2% | −57.0% | −84.4% | −125.4% | −152.4% |
| Return on tangible equity | −23.3% | −75.4% | −69.3% | −268.4% | −209.1% |
| Piotroski F-score | — | — | — | 2 | 2 |
| Altman Z'' | 30.8 | 2.8 | 2.6 | −22.2 | −28.2 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biomea Fusion, Inc. · BMEA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.60 a share, the company is worth $43.4M.
Source: SEC EDGAR XBRL filings (CIK 0001840439). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.